Table 3.
Analysis for time to SARS-CoV-2 clearance.
|
p-value |
||||||
|---|---|---|---|---|---|---|
| Novaferon | LPV/ra + Novaferon | LPV/r | LPV/r vs. Novaferon | LPV/r vs. LPV/r + Novaferon | Novaferon vs. LPV/r + Novaferon | |
| N (Censored) | 30 (13) | 30 (9) | 29 (14) | |||
| Mean (days) | 7.0 | 6.1 | 8.0 | |||
| Median (days)b | 6 | 6 | 9 | 0.417 | 0.036 | 0.183 |
LPV/r: Lopinavir/Ritonavir.
Median time for each group was estimated with the use of the Kaplan–Meier method and treatment differences were tested using the log-rank test.